EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Mango and banana derived resistant starch: Narrative review of biochemical mechanisms, human clinical evidence, and metabolic health

Myntana Kamalanathan

Journal of Multidisciplinary & Translational Research · 30.06.2026 · 11 (1) · 17-29

DOI: 10.4038/jmtr.v11i1.254 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Multidisciplinary & Translational Research, online erschienen am 30.06.2026. Verfasst von Myntana Kamalanathan. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The global rise of obesity, type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) now more commonly termed “metabolic (dysfunction)-associated fatty liver disease” (MAFLD) underscores the need for dietary carbohydrates that mitigate postprandial hyperglycaemia and insulin resistance. Tropical fruits mango (Mangifera indica L.) and banana (Musa spp.) emerge as sustainable sources of resistant starch (RS) types RS2 and RS3 alongside bioactive polyphenols. This review synthesizes biochemical, preclinical and human evidence on mango/banana-derived RS mechanisms within the gut-pancreas-liver axis, highlighting fruit-specific pathways, food matrix interactions and South Asian translational potential. Narrative synthesis of studies on RS classification, structural characterization, phytochemical profiles, glycaemic mechanisms (SCFA production, incretin secretion, epigenetic modulation), gut microbiota remodelling and human intervention trials was conducted. Evidence from mango kernel RS3, green banana RS2 and general RS meta-analyses were integrated with emphasis on Sri Lankan public health relevance. Mango yields retrograded RS3 via processing while green bananas provide native RS2 with B-type crystallinity. Both resist small intestinal digestion, promoting colonic fermentation to short-chain fatty acids (SCFAs) that activate G protein-coupled receptor 41/43 (GPR41/43), stimulate glucagon-like peptide-1 (GLP-1) and enhance insulin sensitivity via AMP-activated protein kinase (AMPK). Human trials demonstrate 15-40 g/day RS reduces fasting glucose, HbA1c and HOMA-IR, particularly in prediabetes/T2DM. However, evidence for mango- and banana-derived RS is predominantly indirect, based on whole fruit consumption studies and general RS meta-analyses rather than trials using isolated mango or banana RS. Nonetheless, mango and banana-derived RS exemplify sustainable functional food ingredients for glycaemic control through complementary structural forms (RS2 and RS3) and phytochemical synergies. Well-powered randomized controlled trials using standardized fruit RS with continuous glucose monitoring endpoints are needed, alongside sustainable byproduct utilization strategies for South Asian metabolic disease prevention.

Zitieren

APA

Kamalanathan, M. (2026). Mango and banana derived resistant starch: Narrative review of biochemical mechanisms, human clinical evidence, and metabolic health. Journal of Multidisciplinary & Translational Research, 11(1), 17-29. https://doi.org/10.4038/jmtr.v11i1.254

Vancouver

Kamalanathan M. Mango and banana derived resistant starch: Narrative review of biochemical mechanisms, human clinical evidence, and metabolic health. Journal of Multidisciplinary & Translational Research. 2026;11(1):17-29. doi:10.4038/jmtr.v11i1.254

BibTeX
@article{Kamalanathan2026,
  author = {Kamalanathan, Myntana},
  title = {Mango and banana derived resistant starch: Narrative review of biochemical mechanisms, human clinical evidence, and metabolic health},
  journal = {Journal of Multidisciplinary & Translational Research},
  year = {2026},
  volume = {11},
  number = {1},
  pages = {17--29},
  doi = {10.4038/jmtr.v11i1.254}
}
Kostenlos starten →